Pas de connexion internet — affichage de la version enregistrée de la page.

Tevogen Bio Holdi…

USUSD
← Vers le Screener

Tevogen Bio Holdings Inc. (US:TVGN) — Biotechnology: Biological Products (No Diagnostic Substances). Nombre de places boursières sur lesquelles les actions de la société sont cotées : 1. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site Web
tevogen.com
Secteur
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Siège Social
WARREN, United States
PDG
Ryan H. Saadi
Employés
18
Actions en Circulation
6.51 M au 2026-08-10
Flottant
843 310
Capitalisation Boursière
45.45 M USD
Initiés
72.08%
Investisseurs Institutionnels
1.65%
Secteur d'Activité (SIC)
Biological Products, (No Diagnostic Substances)
P/E
perte
FCF
−12.4 M USD
Dette
1.01 M USD
Résultats et FCF — pour les 12 mois à 30.06.2026 (dernier rapport de l'entreprise).
NAV
−2.09 USD
Date du Bilan30.06.2026
Actifs4.73 M USD
− Passifs13.6 M USD
= NAV (capitaux propres des actionnaires de la société)−8.89 M USD
= NAV Tangible−8.89 M USD
Actions4 255 107
NAV par Action−2.09 USD
VLV Tangible par Action−2.09 USD
Les capitaux propres sont négatifs : les passifs dépassent les actifs (souvent en raison de rachats importants d'actions). Le PV/NAV n'est pas calculé.
Historique de la NAV
Date du BilanNAVNAV par Action
30.06.2026−8.89 M USD−2.09 USD
31.03.2026−9.84 M USD−2.36 USD
31.12.2025−8.23 M USD−2.05 USD
30.09.2025−7.82 M USD−0.04 USD
30.06.2025−9.48 M USD−0.05 USD
31.03.2025−7.72 M USD−0.04 USD
31.12.2024−6.67 M USD−1.87 USD
30.09.2024−6.19 M USD−0.04 USD
Description

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B. It also offers artificial intelligence platform for drug development. Tevogen Inc. was formerly known as Tevogen Bio Holdings Inc. and changed its name to Tevogen Inc. in July 2026. The company was incorporated in 2020 and is headquartered in Warren, New Jersey.

publicité

Bourses et Tickers

BourseTickerDevisePrixType
US USA StocksTVGNUSD7.08 +8.83%actions ordinaires

Cours sur 3 Mois

US:TVGN · USD
jour de hausse jour de baisseSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas

Principaux Actionnaires

DétenteurParticipationActionsDate du Rapport
KHAN SADIQ (Officer)≈17.96%1.17 M2025-06-27
DESAI KIRTI (Chief Finan…≈15.25%992 9832026-09-14
PATTON CURTIS L (Directo…≈2.14%139 1922026-09-11
FEIKE JEFFREY L (Directo…≈2.02%131 4352026-09-11
SORDILLO VICTOR J (Direc…≈1.94%126 5392026-09-11
GOH KEOW LIN (Director)≈1.9%123 6782026-09-11
PODLOGAR SUSAN M (Direct…≈1.9%123 6782026-09-11
FLOMENBERG NEAL (Officer…≈1.18%76 9402026-03-13
Vanguard Capital Managem…0.15%23 9762026-06-30
Morgan Stanley0.12%18 8092026-06-30
AQR Capital Management,…0.11%17 2372026-06-30
VANGUARD INDEX FUNDS-Van…0.1%15 1022026-06-30
Goldman Sachs Group Inc0.09%14 1632026-06-30
GOLDMAN SACHS TRUST-Gold…0.09%13 9512026-06-30
Jane Street Group, LLC0.07%11 1752026-06-30
FMR, LLC0.06%9 8262026-06-30
VANGUARD Inst. INDEX Fd.…0.04%7 0352026-06-30
Russell Investments Grou…0.04%6 5322026-06-30
Fidelity Concord Street…0.03%4 0812026-07-31
VANGUARD SCOTTSDALE FUND…0.03%4 0532026-05-31
VANGUARD INDEX FUNDS-Van…0.01%1 8392026-06-30
Tower Research Capital L…0.01%1 4942026-06-30
Fidelity Concord Street…0.01%1 4632026-07-31
UBS Group AG0.01%1 0832026-06-30
Vanguard Fiduciary Trust…0.01%8382026-06-30
Fidelity Concord Street…0%3572026-07-31
VANGUARD SCOTTSDALE FUND…0%3142026-05-31
Fidelity Concord Street…0%3002026-07-31
SAADI RYAN H (Chief Exec…—11.71 M2026-09-14